The Disease Severity In Patients With Psoriasis
1 other identifier
observational
33
1 country
1
Brief Summary
This observational study aims to evaluate new markers to predict disease activity in psoriasis. The main question is SGOT, SGPT, GGT, hs-CRP, and apo B related to disease severity in psoriasis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2022
CompletedFirst Submitted
Initial submission to the registry
June 25, 2023
CompletedFirst Posted
Study publicly available on registry
July 13, 2023
CompletedJuly 13, 2023
July 1, 2023
7 months
June 25, 2023
July 4, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Gamma-Glutamyl Transferase
Gamma-Glutamyl Transferase was check in admission, reference range for adults is 5 to 40 U/L (units per liter)
only in admission
Apolipoprotein B
Apolipoprotein B (ApoB) is the primary apolipoprotein and is the carrier for the following lipids: chylomicrons, low-density lipoprotein ( LDL), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein. Unit used in mg/dL
only in admission
High-sensitivity c-reactive protein
High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. Unit used in mg/L
only in admission
PASI
A PASI (The Psoriasis Area and Severity Index) score can range from 0 to 72
only in admission
Eligibility Criteria
Psoriasis Patients
You may qualify if:
- Clinical diagnosis of Psoriasis
You may not qualify if:
- Heart Failure
- Diabetes Mellitus
- Kidney Disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universitas Sebelas Maret Hospital
Sukoharjo, Central Java, 57161, Indonesia
Related Publications (2)
Sholihah MM, Kusuma TRH, Hanif MI, Prabowo NA. Letter to the Editor on Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2021 Sep;58(9):1283-1284. doi: 10.1007/s00592-021-01761-3. Epub 2021 Jun 28. No abstract available.
PMID: 34181079BACKGROUNDPratama YS, Pradiptakirana R, Rachmah A, Prabowo NA. Autoimmune Thrombocytopenia in SLE and COVID-19. Eur J Case Rep Intern Med. 2021 Nov 3;8(11):002863. doi: 10.12890/2021_002863. eCollection 2021.
PMID: 34912736RESULT
Biospecimen
5 cc of blood was drawn for GGT, hs-CRP, and apo B examinations.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Hospital Research Unit
Study Record Dates
First Submitted
June 25, 2023
First Posted
July 13, 2023
Study Start
June 1, 2022
Primary Completion
December 30, 2022
Study Completion
December 30, 2022
Last Updated
July 13, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share